帕博利珠单抗联合放化疗初治间变性甲状腺癌的2期研究
这项研究者发起的2期试验评估帕博利珠单抗联合放化疗作为间变性甲状腺癌一线治疗(联合或不联合手术)的疗效与毒性。计划入组25例,实际仅入组3例,早期肿瘤缓解均良好且完成既定治疗,但3例均于治疗开始后6个月内死亡,研究提前终止。
要点
- 帕博利珠单抗联合放化疗早期局部控制良好且可耐受。
- 3例均于治疗开始后6个月内死亡,生存结局差于历史对照。
- 研究因意外肺部并发症提前终止,该方案需谨慎评估。
核心结论
- 帕博利珠单抗联合放化疗初期可耐受且局部控制有效,但生存结局差于历史对照,提示该方案是否值得进一步探索存在不确定性。
研究设计与样本
- 研究者发起的治疗性2期试验,帕博利珠单抗200 mg静脉每3周联合放化疗(多西他赛/多柔比星各20 mg/m2每周静脉加容积旋转调强放疗)作为间变性甲状腺癌一线治疗(联合或不联合手术)。
- 采用Simon最优设计并设中期分析,目标入组25例(队列A:既往切除;队列B:未切除),主要终点为6个月总生存。
主要发现
- 实际入组3例,其中2例为快速增大的不可切除颈部肿块。
- 3例早期肿瘤缓解均良好,且均满意完成预定放疗、放疗前后帕博利珠单抗及同步放化疗。
- 3例均于治疗开始后6个月内死亡:1例死于肺转移,2例死于放化疗完成后意外发生的致命性肺部并发症。
关键数值与推荐
- 基于既往无帕博利珠单抗的类似治疗队列,设计假设若6个月真实生存率为75%,则宣布该方案值得进一步 pursue 的概率为91%。
临床怎么用
- 该联合方案在间变性甲状腺癌中虽早期局部控制良好,但生存结局令人失望,临床应谨慎评估其风险获益。
局限性
- 实际仅入组3例即因意外死亡提前终止,样本量远低于计划,无法得出可靠疗效结论。
- 2例意外致命性肺部并发症的具体机制未明,可能影响安全性判断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Anaplastic thyroid cancer (ATC) has poor prognosis with median overall survival (OS) of ∼6 months. We previously reported high PD-1/PDL-1 staining in ATC, raising the possibility of the productive application of the immunotherapeutic pembrolizumab. However, having found pembrolizumab to anecdotally have limited single-agent activity in ATC, we sought to alternatively define whether pembrolizumab might synergistically combine with chemoradiotherapy as initial ATC therapy. Methods: An investigator-initiated therapeutic phase 2 trial of pembrolizumab, 200 mg intravenously (IV) every 3 weeks, combined with chemoradiotherapy (docetaxel/doxorubicin, 20 mg/m2 each IV weekly plus volumetric modulated arc therapy) was initiated as frontline therapy (with or without surgery) in ATC to assess efficacy and toxicities. Six-month OS was selected as the primary endpoint using a Simon's optimal design with interim analysis (targeting accrual of 25 patients; Cohort A: prior resection, Cohort B: no resection). Based on a prior patient cohort-treated similarly, but without pembrolizumab, the design was such that, if 6-month true survival is 75%, the probability of declaring the approach worthy of further pursuit would be 91%. Results: Three patients were enrolled, two with rapidly enlarging unresectable neck masses. Early tumor responses were favorable in all three, and all three satisfactorily completed: intended radiotherapy, preceding and radiotherapy-concurrent pembrolizumab, and concurrent chemoradiotherapy. However, all three patients died <6 months following therapy initiation-one from pulmonary metastases and two from otherwise unexpected fatal pulmonary complications occurring subsequent to chemoradiotherapy completion-prompting study closure. Conclusions: Although initially tolerated and effective in terms of locoregional disease control, disappointing survival outcomes compared with historical controls raise uncertainty that the piloted approach merits further pursuit in ATC.
引用
- Chintakuntlawar AV, Yin J, Foote RL, et al. A Phase 2 Study of Pembrolizumab Combined with Chemoradiotherapy as Initial Treatment for Anaplastic Thyroid Cancer. Thyroid. 2019. PMID: 31595822. doi:10.1089/thy.2019.0086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。